| アブストラクト | BACKGROUND: The aim of this study was to analyse the risk of uncomplicated peptic ulcer disease (PUD) in a cohort of new users of low-dose acetylsalicylic acid (ASA) for secondary prevention of cardiovascular events in a UK primary care setting. METHODS: New users of low-dose ASA for secondary prevention of cardiovascular events, aged 50-84 years in 2000-2007, were identified from The Health Improvement Network. Among those 38,975 individuals, 309 patients were considered to be incident cases of uncomplicated PUD. Incidence of uncomplicated PUD was calculated and a nested case-control analysis adjusted for potential confounding factors was performed to calculate the odds ratios (ORs) for the association of potential risk factors with uncomplicated PUD. RESULTS: The crude incidence of uncomplicated PUD was 1.41 per 1000 person-years (95% confidence interval [CI], 1.26-1.58). Individuals with a history of PUD were more likely to develop uncomplicated PUD than those without such a history (hazard ratio [HR], 2.22, 95% CI, 1.60-3.09). In nested case-control analyses, the risk of uncomplicated PUD was associated with current use of non-steroidal anti-inflammatory drugs, oral steroids or acid suppressants. Other risk factors for developing uncomplicated PUD included smoking, stress, depression, anaemia and social deprivation. CONCLUSION: Our results indicate that several risk factors significantly increase the risk of development of uncomplicated PUD in new users of low-dose ASA. Therefore, physicians should monitor ASA users for gastrointestinal symptoms and signs of ulcer, particularly if they have additional risk factors. |
|---|
| ジャーナル名 | BMC gastroenterology |
|---|
| Pubmed追加日 | 2014/12/11 |
|---|
| 投稿者 | Ruigomez, Ana; Johansson, Saga; Nagy, Peter; Martin-Perez, Mar; Rodriguez, Luis A Garcia |
|---|
| 組織名 | Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Almirante 28-2, E;28004, Madrid, Spain. aruigomez@ceife.es.;AstraZeneca R&D, Pepparedsleden 1, Molndal, SE-431 83, Sweden.;Saga.Johansson@astrazeneca.com.;Peter.Nagy@astrazeneca.com.;28004, Madrid, Spain. mar.martinpe@gmail.com.;28004, Madrid, Spain. lagarcia@ceife.es. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/25492031/ |
|---|
